Dr. Mason Lu is the founder, President and CEO of MedAbome, Inc. Dr. Mason Lu is an expert in immunology, oncology and antibody Science/Technology with over 30 years of experiences in discovery and development of therapeutic antibodies. Dr. Lu is the original inventor of EBGLYSS® (Lebrikizumab) and has participated in antibody validation and assay development of Xolair® (Omalizumab), Ligelizumab, and Trogarzo® (Ibulizumab). He also holds co-inventorships of many other antibody drug candidates that are currently under different development stages. 

Dr. Mason Lu is a serial entrepreneur who has successfully founded two antibody companies in China prior to MedAbome, Inc. Formerly he was a Scientist/Research Manager II in Tanox/Genentech, Inc., an Assistant Professor in Dept. of Surgical Oncology of UT-MD Anderson Cancer Center in Houston, Texas.

Dr. Mason Lu received Ph.D. from MRC-LMB and University of Cambridge, M.D. from Shanghai Second Medical University, and M.Sc. from Shanghai Cancer Institute. He received postdoctoral trainings in Baylor College of Medicine.